SC 58125
Biological Activity
Selective cyclooxygenase 2 (COX-2) inhibitor (IC50 values are 0.04 and >100 μM for COX-2 and COX-1 respectively). Anti-inflammatory; blocks edema and hyperalgesia in vivo following an inflammatory insult, without causing gastric mucosal damage. Also displays antitumor activity.
Licensing Information
Sold for research purposes under agreement from Pfizer Inc.
Technical Data
| M. Wt | 384.35 |
| Formula | C17H12F4N2O2S |
| Storage | Store at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 162054-19-5 |
| PubChem ID | 115239 |
| InChI Key | JHBIMJKLBUMNAU-UHFFFAOYSA-N |
| Smiles | FC(C=C3)=CC=C3C1=CC(C(F)(F)F)=NN1C2=CC=C(S(=O)(C)=O)C=C2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 38.44 | 100 | |
| ethanol | 9.61 | 25 |
Preparing Stock Solutions
The following data is based on the product molecular weight 384.35. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.6 mL | 13.01 mL | 26.02 mL |
| 5 mM | 0.52 mL | 2.6 mL | 5.2 mL |
| 10 mM | 0.26 mL | 1.3 mL | 2.6 mL |
| 50 mM | 0.05 mL | 0.26 mL | 0.52 mL |
Molarity Calculator
Reconstitution Calculator
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Gierse et al (1996) A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J.Biol.Chem. 271 15810 PMID: 8663121
Williams et al (2001) A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established colon cancer xenografts. Neoplasia 3 428 PMID: 11687954
Seibert et al (1994) Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc.Natl.Acad.Sci.USA 91 12013 PMID:
If you know of a relevant reference for SC 58125, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: SC 58125, supplier, Selective, cyclooxygenase-2, COX-2, inhibitors, inhibits, Oxygenases, Oxidases, SC58125, Pfizer, Cyclooxygenase, Tocris Bioscience
Citations for SC 58125
Citations are publications that use Tocris products.
Currently there are no citations for SC 58125. Do you know of a great paper that uses SC 58125 from Tocris? If so please let us know.
Literature in this Area
Cancer Research Product Guide
A collection of over 750 products for cancer research, the guide includes research tools for the study of:
- Cancer Metabolism
- Epigenetics in Cancer
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Angiogenesis
- Invasion and Metastasis
Immunology Product Listing
A collection of over 190 products for immunology research, the guide includes research tools for the study of:
- Chemokine and Cytokine Signaling
- Chemotaxis
- Complement System
- Immune Cell Signaling
- Inflammation
Pain Research Product Guide
A collection of over 250 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Alzheimer's Poster
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Asthma Poster
Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.
Parkinson's Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
